News

Jason Westin, MD, FASCP, the director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center, discussed factors that limit patient access to treatment and a potential solution.

The director of the Medical Oncology Service at the National Cancer Institute discussed the START-001 trial.

The new analysis is from a phase 1 trial of Celularity’s legacy MLASC therapy.

The new data from the TRANSCEND FL and TRANSCEND NHL 001 studies are the latest in a series of positive updates regarding liso-cel that have been announced by Bristol Myers Squibb in recent months.

The director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center discussed axi-cel's safety profile and an important factor for improving access to CAR-T therapies.

Review top news and interview highlights from the week ending June 23, 2023.

A phase 1/1b clinical trial is planned to evaluate the safety and efficacy of the therapy.

The associate professor from Dana Farber Cancer Center and Harvard Medical School discussed continued efficacy and safety data presented at the 2023 EHA Meeting.

Jason Westin, MD, FASCP, the director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center, discussed the implications of data he presented at ASCO’s 2023 conference.

The company stated that this year it plans to initiate a single dosage study that will serve as a subgroup of a larger phase 3 clinical trial.

The assistant professor at MD Anderson Cancer Center discussed new data she presented at the 2023 ASCO Meeting.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

uniQure deemed the safety profile for AMT-130 to be manageable.

The assistant professor in the Division of Lymphoma at City of Hope discussed the potential implications of real-world data she presented at ASCO’s 2023 conference.

Data from a phase 1/2 clinical trial of NRTX-1001 were presented at the ISSCR 2023 Annual Meeting.

The company believes that limitations on bridging therapies were a contributing factor to the death.

The director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center discussed recent and ongoing studies that are upending the paradigm in LBCL care.

More work remains to be done to improve accessibility to populations and countries that have the highest unmet need with SCD treatment.

The company will instead prioritize further development of its oral arsenic trioxide platform for cGvHD.

The assistant professor of medicine at University of Alabama – Birmingham discussed efficacy findings on BMS-986983 and more research to be done.

The advocacy groups are funding a 1-year study to be led by Barry Byrne, MD, PhD, at University of Florida.

The director of University of Washington Medicine’s Cancer Vaccine institute discussed the importance of continuing to develop new CAR-T approaches in the ovarian cancer field despite initial setbacks.

The BASECAMP-1 clinical trial will aim to find patients with advanced solid tumors who are good candidates for the subsequent EVEREST trial.

Two of 6 patients in the WM cohort achieved a complete response and 16 of 20 patients in the FL cohort achieved a complete response.

Review top news and interview highlights from the week ending June 16, 2023.

CGTLive takes a look at challenges that have beset the first gene therapy coming close to market for treating Duchenne muscular dystrophy in 2023.

The assistant professor of medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University discussed potential methods for optimizing CAR-T efficacy that could be explored in the future.

The phase 1/2 Euplagia-1 trial is currently ongoing in Europe.